Dr. Reddy's Laboratories Limited (BVMF:R1DY34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 61.77B -11.8% |
| Revenue (ttm) | 18.69B +3.2% |
| Net Income | 2.38B -24.2% |
| EPS | 2.86 -24.1% |
| Shares Out | n/a |
| PE Ratio | 25.91 |
| Forward PE | 25.57 |
| Dividend | 0.06 (0.52%) |
| Ex-Dividend Date | Jul 9, 2025 |
| Volume | 1 |
| Open | 12.06 |
| Previous Close | n/a |
| Day's Range | 12.06 - 12.06 |
| 52-Week Range | 10.80 - 14.09 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 22, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as ... [Read more]
Financial Performance
In fiscal year 2026, Dr. Reddy's Laboratories's revenue was 335.93 billion, an increase of 3.19% compared to the previous year's 325.54 billion. Earnings were 42.85 billion, a decrease of -24.22%.
Financial numbers in INR Financial StatementsNews
Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanDepositaryReceipts--Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F.
Is It Too Late to Buy Dr Reddy's Laboratories Ltd (RDY) After 4.0% Rally? GF Value Says Undervalued
Is It Too Late to Buy Dr Reddy's Laboratories Ltd (RDY) After 4.0% Rally? GF Value Says Undervalued
Dr. Reddy's Laboratories receives seven USFDA observations at Hyderabad facility
Dr. Reddy's Laboratories has announced that the United States Food & Drug Administration (USFDA) completed a Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderab...
Pharma sector stocks today, June 25: Panacea Biotec rises 3.26%, Dr. Reddy's Lab up 2.01%, Orchid Pharma falls 1.70%
Pharma stocks traded with a mixed-to-positive bias on June 25, 2026, during the early morning session, with several mid-cap names posting healthy gains while a few counters slipped into the…
Pharma sector stocks today, June 24: Orchid Pharma up 3.72%, Dr. Reddys Lab gains 2.38%, Panacea Biotech falls 1.18%
Pharma stocks traded broadly in positive territory on June 24, 2026, during the early morning session, with most stocks posting modest gains. The broader market was largely flat, with the…
Pharma sector stocks rally today, June 23: IPCA Labs up 2.54%, Dr. Reddys Lab gains 2.47%, Natco Pharma rises 2.45%
Pharma stocks saw strong broad-based gains on June 23, 2026, during the early morning session, with almost all stocks trading in the green. The broader market was largely flat, with…
Dr Reddy's Laboratories Ltd (RDY) Stock Up 4.7% and Still Undervalued -- GF Score: 88/100
Dr Reddy's Laboratories Ltd (RDY) Stock Up 4.7% and Still Undervalued -- GF Score: 88/100
Bullish Two Hundred Day Moving Average Cross - RDY
In trading on Monday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $13.85, changing hands as high as $14.03 per share. Dr. Reddy's Laboratories L...
Dr. Reddy's Laboratories issues 6,730 equity shares under ESOPs
Dr. Reddy's Laboratories has announced the allotment of 6,730 equity shares to eligible employees following the exercise of stock options. This allotment, which took place on 19 June 2026, is…
Dr. Reddy's Laboratories (RDY) Secures License for XACDURO Distribution
Dr. Reddy's Laboratories (RDY) Secures License for XACDURO Distribution
Innoviva announces distribution, licensing agreement with Dr. Reddy’s
Innoviva Specialty Therapeutics, a subsidiary of Innoviva (INVA), announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories (RDY) for the devel...
Dr. Reddy's Laboratories (RDY) Faces 15% Drop Amid Market Movements
Dr. Reddy's Laboratories (RDY) Faces 15% Drop Amid Market Movements
Stocks to watch on June 15: Aurobindo Pharma, Patanjali Foods, Cyient, Dr Reddy's, JSW Energy, Aditya Birla Capital and more
Indian equities head into Monday's session with a heavy mix of corporate actions, regulatory developments, fundraises and order wins across pharma, power, capital markets and infrastructure. Adding to...
Dr. Reddy's (RDY) Launches Generic Bosutinib Tablets in the U.S.
Dr. Reddy's (RDY) Launches Generic Bosutinib Tablets in the U.S.
Dr. Reddy’s announces first-to-market launch of Bosutinib Tablets 400mg
Dr. Reddy’s (RDY) Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, expanding its oncology portfolio and reinforcing ...
Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bosulif--Dr. Reddy's Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif® i...
Dr. Reddy's launches Bosutinib Tablets 400mg in the United States
Dr. Reddy’s Laboratories Ltd. has announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States. This launch enhances Dr. Reddy’s oncology por...
Nomura on Pharma May 2026: Torrent leads semaglutide with 19% market share, Sun gains; Alkem and Dr Reddy's lag market
Global brokerage Nomura has highlighted Torrent Pharmaceuticals as the standout performer among its India pharma coverage in May 2026, with the company recording the strongest growth in the Indian Pha...
Dr. Reddy's Laboratories issues 12,100 equity shares under stock options scheme
Dr. Reddy's Laboratories has announced the allotment of 12,100 equity shares to eligible employees following the exercise of stock options under its Employees Stock Options Scheme, 2002, and Employees...
Dr. Reddy's files 20-F annual report with US SEC for fiscal year ended March 31, 2026
Dr. Reddy's Laboratories has filed its Form 20-F annual report with the United States Securities and Exchange Commission (SEC), the company announced on May 30, 2026. The filing contains consolidated…
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 29, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NY...
Dr Reddy’s to ring closing bell at NYSE to mark 25 years of its listing
Dr Reddy’s Laboratories will ring the NYSE closing bell on May 30 to mark 25 years since its 2001 listing, a first for an Asian pharma firm outside Japan.
Dr. Reddy's Laboratories to ring the Closing Bell at NYSE for 25th listing anniversary
Dr. Reddy’s Laboratories Ltd. is set to ring the Closing Bell® at the New York Stock Exchange (NYSE) on May 29, 2026, marking 25 years since its listing. The company…
Dr Reddy’s rolls out oral semaglutide in India
Dr Reddy’s launches oral semaglutide biosimilar Obeda in India for Type 2 diabetes, CDSCO-approved; once-daily tablets priced Rs 99–225 (3/7/14 mg).
Dr. Reddy's (RDY) Introduces Generic Semaglutide Injection in Canada
Dr. Reddy's (RDY) Introduces Generic Semaglutide Injection in Canada